Siponimod (BAF312, Mayzent) was the first new-generation sphingosine-1-phosphate receptor (S1PR) modulator, which was already approved for relapsing and progressive MS by FDA and for active secondary progressive MS by EMA. The gene discussed is S1PR1; the disease is myeloid sarcoma.